Search Results - "Nummy, Laurence J."
-
1
Formation of 2-Trifluoromethylphenyl Grignard Reagent via Magnesium−Halogen Exchange: Process Safety Evaluation and Concentration Effect
Published in Organic process research & development (20-11-2009)“…The thermal stability profile for a solution of 2-trifluoromethylphenyl magnesium chloride at 1.5 M concentration in THF was determined using an Advanced…”
Get full text
Journal Article -
2
Synthesis of a Sodium–Hydrogen Exchange Type 1 Inhibitor: An Efficient Cu-Catalyzed Conjugated Addition of a Grignard Reagent to an Acetyl Pyridinium Salt
Published in Organic process research & development (15-03-2013)“…A facile and economical five-step process for the synthesis of a sodium–hydrogen exchange type I inhibitor (NHE-1) was developed from readily available…”
Get full text
Journal Article -
3
Process Safety Evaluation of a Magnesium−Iodine Exchange Reaction
Published in Organic process research & development (17-11-2006)“…An unexpected highly exothermic decomposition was observed during routine safety analysis of the magnesium−iodine exchange reaction of 2-iodo-4-fluorotoluene…”
Get full text
Journal Article -
4
Practical Synthesis of an Enantiomerically Pure trans-4,5-Disubstituted 2-Pyrrolidinone via Enzymatic Resolution. Preparation of the LTB4 Inhibitor BIRZ-227
Published in Journal of organic chemistry (23-01-1998)“…A practical synthesis of the enantiomerically pure BIRZ-227 (1), a LTB4 inhibitor, has been developed. The key steps include the effective synthesis of the…”
Get full text
Journal Article -
5
Practical synthesis of a cell adhesion inhibitor by self-regeneration of stereocenters
Published in Tetrahedron: asymmetry (14-11-2003)“…An efficient enantiospecific synthesis of the cell adhesion inhibitor BIRT-377 by self-regeneration of stereocenters has been achieved in 38% overall yield in…”
Get full text
Journal Article -
6
Synthesis of five nevirapine metabolites
Published in Journal of heterocyclic chemistry (01-03-2000)“…Nevirapine (1) is a non‐nucleoside reverse transcriptase inhibitor marketed for HIV treatment by Boehringer Ingelheim as Viramune® since 1996. In vitro studies…”
Get full text
Journal Article -
7